top of page

Funding the next breakthrough in brain cancer research.



This is Knox.

This photo of Knox was taken in Bray, Ireland, in July of 2018 by Knox’s best friend, his brother Riley. Knox was cancer-free and enjoying the great outdoors – a source of constant inspiration for him.
Along the rocky shores of life Knox is moving forward and so shall we in the fight against Glioblastoma.

Despite being first identified in the scientific literature in the 1920s, there are only four FDA-approved drugs to treat Glioblastoma (GBM). Four in 100 years. For GBM, the five-year relative survival rate is only 7.2% and median survival is only 8 months.

These devastating statistics attest to the severely underfunded and under-researched nature of brain cancer treatments – particularly treatments for GBM. Few research studies are conducted in aggressive brain cancers each year because the disease is so deadly; yet the disease remains deadly because so few research studies exist. Our goal is to end this infinite loop. 

Our mission is to fund innovative research on aggressive brain cancers to give patients a shot at a longer life. Our vision is a world where a GBM diagnosis is treatable and curable.


We work directly with medical research partners at the Preston Robert Tisch Brain Tumor Center at Duke to fund innovative research for clinical trials and life saving treatments

bottom of page